Skip to main content

Table 2 Results of Cox regression analysis for the effects of albuminuria and retinopathy on (A) all-cause and (B) cardiovascular mortality

From: Inpatient screening for albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a retrospective cohort study

  Crude Crude Crude Crude
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
(A) All-cause-mortality
 Albuminuria(−)/Retinopathy(−) 1    1       1   
 Albuminuria(−)/Retinopathy(+) 1.575 (1.230, 2.018) <0.001 1.402 (1.092, 1.801) 0.008 1.529 (1.142, 2.047) 0.004 1.524 (1.138, 2.041) 0.005
 Albuminuria(+)/Retinopathy(−) 2.714 (1.969, 3.741) <0.001 2.465 (1.784, 3.405) <0.001 2.550 (1.772, 3.671) <0.001 2.551 (1.771, 3.676) <0.001
 Albuminuria(+)/Retinopathy(+) 2.241 (1.739, 2.887) <0.001 2.215 (1.718, 2.856) <0.001 2.213 (1.626, 3.014) <0.001 2.200 (1.613, 3.001) <0.001
(B) Cardiovascular mortality
 Albuminuria(−)/Retinopathy(−) 1    1    1    1   
 Albuminuria(−)/Retinopathy(+) 2.519 (1.731, 3.664) <0.001 2.155 (1.478, 3.144) <0.001 2.412 (1.550, 3.752) <0.001 2.434 (1.562, 3.794) <0.001
 Albuminuria(+)/Retinopathy(−) 3.264 (1.955, 5.448) <0.001 2.858 (1.707, 4.785) <0.001 2.866 (1.610, 5.105) <0.001 2.762 (1.551, 4.917) <0.001
 Albuminuria(+)/Retinopathy(+) 3.489 (2.376, 5.123) <0.001 3.440 (2.340, 5.057) <0.001 3.339 (2.094, 5.326) <0.001 3.327 (2.080, 5.321) <0.001
  1. Statistical significance (P < 0.05) is indicated in italics
  2. HR hazard ratio, CI confidence interval
  3. Model 1: adjusted for age and gender
  4. Model 2: adjusted for age, gender, body mass index, systolic blood pressure, current smoker, diabetes duration, glycated hemoglobin, chronic kidney disease [estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2], total cholesterol and triglycerides
  5. Model 3: adjusted for age, gender, body mass index, systolic blood pressure, current smoker, diabetes duration, glycated hemoglobin, chronic kidney disease (eGFR <60 mL/min/1.73 m2), total cholesterol, triglycerides, insulin treatment and angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment